Kyndryl reaffirmed its full-year outlook and said its latest results keep it on track to meet long-term targets.

IT infrastructure services provider Kyndryl (NYSE:KD) fell short of the market’s revenue expectations in Q2 CY2025, with ...

Vertex Pharmaceuticals (VRTX) stock is sliding after the company said it won't advance its pain treatment into the next phase ...

Shares of Kyndryl sank after the company recorded flat revenue in the latest completed quarter, missing analyst targets. The stock was down 19% at $29.82 in early trading. Shares are now in negative ...

Kyndryl Holdings has announced a remarkable increase in its first-quarter profits, soaring over five-fold thanks to strategic ...

Despite all of the positivity mentioned by Schroeter, it didn’t mask the fact that the company’s guidance came up short of ...

Kyndryl Holdings (NYSE:KD) fell more than 10% during early post-market trading after the company reported its first quarter ...

Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today released financial results ...

Kyndryl Holdings (NYSE:KD) shares sank 16% during early market trading on Tuesday after its first quarter fiscal 2026 financial results demonstrated a slight revenue decline in constant currency.

Within the next 20 months, the drag from contracts signed from when Kyndryl was part of IBM will be negligible, Kyndryl ...

The company reported adjusted pretax income of $128 million, a 39% increase from the prior-year period, while adjusted EBITDA rose 16% YoY to $647 million. Kyndryl’s hyperscaler-related revenue grew ...

"We're buyers of dips": Mike Wilson, strategist at Morgan Stanley ( MS 1.58%), said he expects a "modest pullback in the ...